.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free and general survival, leading to FDA approval and a brand-new procedure option for individuals.